Gossamer Bio (GOSS) to Post Quarterly Earnings on Tuesday

Gossamer Bio (NASDAQ:GOSS) is anticipated to issue its Q2 2026 results before the market opens on Tuesday, August 4th. Analysts expect Gossamer Bio to post earnings of ($0.08) per share and revenue of $4.2960 million for the quarter. Investors can check the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Friday, August 7, 2026 at 4:00 PM ET.

Gossamer Bio (NASDAQ:GOSS) last posted its quarterly earnings results on Friday, May 15th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by ($0.03). The business had revenue of $16.95 million for the quarter, compared to analysts’ expectations of $4.67 million. On average, analysts expect Gossamer Bio to post $-0 EPS for the current fiscal year and $-0 EPS for the next fiscal year.

Gossamer Bio Price Performance

Shares of GOSS stock opened at $0.23 on Tuesday. The company has a fifty day moving average price of $0.18 and a two-hundred day moving average price of $0.80. Gossamer Bio has a one year low of $0.11 and a one year high of $3.87. The stock has a market cap of $54.92 million, a P/E ratio of -0.31 and a beta of 2.04.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on GOSS shares. HC Wainwright reaffirmed a “buy” rating on shares of Gossamer Bio in a report on Monday. Weiss Ratings cut Gossamer Bio from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, May 19th. Finally, Leerink Partners raised Gossamer Bio from a “market perform” rating to an “outperform” rating and set a $1.00 price target on the stock in a research report on Tuesday. Four investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have given a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $3.20.

Hedge Funds Weigh In On Gossamer Bio

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Beacon Pointe Advisors LLC bought a new position in Gossamer Bio during the fourth quarter worth $34,000. Ieq Capital LLC bought a new position in shares of Gossamer Bio in the fourth quarter valued at about $35,000. Janney Montgomery Scott LLC bought a new position in shares of Gossamer Bio in the fourth quarter valued at about $39,000. Cibc World Markets Corp acquired a new stake in shares of Gossamer Bio during the 4th quarter worth about $39,000. Finally, O Shaughnessy Asset Management LLC acquired a new stake in shares of Gossamer Bio during the 4th quarter worth about $41,000. 81.23% of the stock is owned by institutional investors.

Gossamer Bio Company Profile

Gossamer Bio, Inc is a clinical-stage biopharmaceutical company headquartered in San Diego, California. Founded in 2012, the company is focused on discovering and developing oral, once-daily therapies for immune-mediated and inflammatory diseases, as well as oncology indications. Gossamer Bio leverages a deep pipeline of small-molecule candidates aimed at improving patient outcomes in areas of high unmet need.

The company’s lead programs include GB004, an S1P1 receptor modulator in late-stage development for ulcerative colitis, and GB1275, a CD11b modulator being investigated in solid tumors and hematologic malignancies.